We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.89%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.82B
AUM Growth
+$296M
Cap. Flow
+$80.3M
Cap. Flow %
4.42%
Top 10 Hldgs %
36.79%
Holding
155
New
17
Increased
81
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$21.6M
2
HUM icon
Humana
HUM
+$21.3M
3
TDOC icon
Teladoc Health
TDOC
+$18.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.4M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$9.38M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$56M
2
AMGN icon
Amgen
AMGN
+$5.81M
3
BIIB icon
Biogen
BIIB
+$5.29M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$5.16M
5
MGNX icon
MacroGenics
MGNX
+$4.78M

Sector Composition

Rank Sector Weight
1 Healthcare 91.35%
2 Industrials 1.12%
3 Technology 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
126
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.06M 0.06%
14,500
-9,500
-40% -$646K
LH icon
127
Labcorp
LH
$24.3B
$894K 0.05%
6,804
-762
-10% -$93.9K
ZLAB icon
128
Zai Lab
ZLAB
$2.17B
$885K 0.05%
+30,000
New +$821K
MDCO
129
DELISTED
Medicines Co
MDCO
$811K 0.04%
+29,000
New +$683K
MCK icon
130
McKesson
MCK
$98.5B
$724K 0.04%
6,186
-693
-10% -$85.5K
AFMD
131
DELISTED
Affimed
AFMD
$704K 0.04%
16,750
-250
-1% -$8.99K
PBYI icon
132
Puma Biotechnology
PBYI
$406M
$663K 0.04%
+17,100
New +$522K
KURA icon
133
Kura Oncology
KURA
$922M
$486K 0.03%
+29,300
New +$451K
VAR
134
DELISTED
Varian Medical Systems, Inc.
VAR
$398K 0.02%
2,807
-315
-10% -$41.4K
GILD icon
135
CALL
Gilead Sciences
GILD
$161B
$174K 0.01%
+600
New +$39.9K
LKFT
136
PUT
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$23K ﹤0.01%
+190
New +$19.2K
ABBV icon
137
PUT
AbbVie
ABBV
$458B
$9K ﹤0.01%
+200
New +$16.4K
ADAP
138
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-131,135
Closed -$754K
BMRN icon
139
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-45,969
Closed -$3.91M
CLLS
140
Cellectis
CLLS
$286M
– –
-46,750
Closed -$778K
HCSG icon
141
Healthcare Services Group
HCSG
$1.56B
– –
-15,000
Closed -$603K
IOVA icon
142
Iovance Biotherapeutics
IOVA
$2.23B
– –
-16,000
Closed -$142K
IRWD icon
143
Ironwood Pharmaceuticals
IRWD
$611M
– –
-91,341
Closed -$793K
LGND icon
144
Ligand Pharmaceuticals
LGND
$6.02B
– –
-38,264
Closed -$3.24M
MYGN icon
145
Myriad Genetics
MYGN
$530M
– –
-31,900
Closed -$927K
NTLA icon
146
Intellia Therapeutics
NTLA
$1.5B
– –
-15,834
Closed -$216K
OEF icon
147
CALL
iShares S&P 100 ETF
OEF
$19.8B
– –
-200
Closed -$70M
TEVA icon
148
Teva Pharmaceuticals
TEVA
$35.9B
– –
-60,000
Closed -$925K
VYGR icon
149
Voyager Therapeutics
VYGR
$187M
– –
-27,900
Closed -$262K
ITCI
150
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-52,600
Closed -$599K
3 4 5
6
7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2019 Portfolio in Review

As of Q1 2019, Bellevue Group held 155 positions worth $1.82B, up 19% from $1.52B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group deployed $80.3M of net new capital in Q1 2019, opening 17 new positions and adding to 81 existing holdings. Its largest new stake was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Celgene Corp, an estimated $56M trimmed.

  • Bellevue Group's largest Q1 2019 buy was Avedro, Inc Common Stock: 750,000 shares worth $9.2M.
  • Bellevue Group added most to Evolent Health in Q1 2019, an estimated $21.6M increase.
  • Bellevue Group's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $56M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q1 2019, selling an estimated $3.91M.
  • Bellevue Group's ten largest holdings make up 37% of its $1.82B portfolio in Q1 2019.
  • Bellevue Group opened 17 new positions and closed 18 in Q1 2019.
  • Bellevue Group's portfolio value rose 19% quarter-over-quarter to $1.82B.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.